Clinical Trial: Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer

U.S., June 28 -- ClinicalTrials.gov registry received information related to the study (NCT07041437) titled 'Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer' on June 19.

Brief Summary: Our study is aimed to evaluate the efficacy and safety of SHR-A2102 combined other antitumor treatments in advanced breast cancer.

Study Start Date: June 30

Study Type: INTERVENTIONAL

Condition: Advanced Breast Cancer

Intervention: DRUG: SHR-A2102

ADC

DRUG: Adebrelimab

PD-L1 inhibitor

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Fudan University

Information provided by (Responsible Party): Hongxia Wang, Fudan University

Disclaimer: Curated by HT Syndication....